MAP2K7 and melanoma: Inhibition of BRAF by MBZ has been confirmed subsequently in a melanoma model, where MBZ was shown to synergize with the MEK inhibitor trametinib to inhibit the growth of BRAFWT-NRASQ61K melanoma cells and xenografts [187]; in addition, MBZ-dependent inhibition of the RAF/MEK/ERK pathway has been demonstrated also in a murine model of hepatocarcinoma [190], pointing out MBZ as a novel BRAF inhibitor.